Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Mills

Showing results (1-10 of 114) with videos related to

Pageof 12
Sort By:
HIV/AIDS Policy & Law Review|December 22, 2005
Tenofovir trials raise ethical issuesEdward Mills
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 6, 2005
More on India's HIV-1 epidemicEdward Mills
Science (New York, N.Y.)|October 21, 2006
HIV testing and individual rightsEdward Mills, Stuart Rennie
The Lancet. Global Health|February 18, 2022
Fluvoxamine for the treatment of COVID-19 - Author's replyGilmar Reis, Edward Mills
Lancet (London, England)|October 10, 2006
Cautious optimism for new HIV/AIDS prevention strategiesEdward Mills, Nandi Siegfried
Journal of Alternative and Complementary Medicine (New York, N.Y.)|September 15, 2006
Diagnostic accuracy among the allied health professions: commentary on Grace et AlDugald Seely, Edward Mills
Journal of Alternative and Complementary Medicine (New York, N.Y.)|March 5, 2003
Closing comment: Evidence-based complementary and alternative medicine: is it a viable concept?Kumanan Wilson, Edward Mills
Clinical Epidemiology|May 10, 2012
Stability of additive treatment effects in multiple treatment comparison meta-analysis: a simulation studyKristian Thorlund, Edward Mills
Journal of Alternative and Complementary Medicine (New York, N.Y.)|January 28, 2005
n-of-1 randomized controlled trials: an opportunity for complementary and alternative medicine evaluationBradley C Johnston, Edward Mills
Clinical Epidemiology|September 25, 2010
Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individualsKristian Thorlund, Aranka Anema, Edward Mills
Pageof 12

Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
HIV/AIDS Policy & Law Review|December 22, 2005
Tenofovir trials raise ethical issuesEdward Mills
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 6, 2005
More on India's HIV-1 epidemicEdward Mills
Science (New York, N.Y.)|October 21, 2006
HIV testing and individual rightsEdward Mills, Stuart Rennie
The Lancet. Global Health|February 18, 2022
Fluvoxamine for the treatment of COVID-19 - Author's replyGilmar Reis, Edward Mills
Lancet (London, England)|October 10, 2006
Cautious optimism for new HIV/AIDS prevention strategiesEdward Mills, Nandi Siegfried
Journal of Alternative and Complementary Medicine (New York, N.Y.)|September 15, 2006
Diagnostic accuracy among the allied health professions: commentary on Grace et AlDugald Seely, Edward Mills
Journal of Alternative and Complementary Medicine (New York, N.Y.)|March 5, 2003
Closing comment: Evidence-based complementary and alternative medicine: is it a viable concept?Kumanan Wilson, Edward Mills
Clinical Epidemiology|May 10, 2012
Stability of additive treatment effects in multiple treatment comparison meta-analysis: a simulation studyKristian Thorlund, Edward Mills
Journal of Alternative and Complementary Medicine (New York, N.Y.)|January 28, 2005
n-of-1 randomized controlled trials: an opportunity for complementary and alternative medicine evaluationBradley C Johnston, Edward Mills
Clinical Epidemiology|September 25, 2010
Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individualsKristian Thorlund, Aranka Anema, Edward Mills
Pageof 12